4,191 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Purchased by EP Wealth Advisors LLC

EP Wealth Advisors LLC acquired a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,191 shares of the company's stock, valued at approximately $483,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. State Street Corp lifted its position in shares of Neurocrine Biosciences by 11.7% in the third quarter. State Street Corp now owns 5,148,293 shares of the company's stock valued at $593,186,000 after buying an additional 539,936 shares during the last quarter. 1832 Asset Management L.P. boosted its stake in Neurocrine Biosciences by 1,370.7% in the 2nd quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company's stock valued at $74,507,000 after purchasing an additional 504,400 shares during the period. Los Angeles Capital Management LLC grew its holdings in Neurocrine Biosciences by 639.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company's stock valued at $48,479,000 after buying an additional 363,863 shares in the last quarter. AQR Capital Management LLC increased its position in Neurocrine Biosciences by 23.0% during the 2nd quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company's stock worth $166,959,000 after buying an additional 228,444 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of Neurocrine Biosciences by 9.6% during the second quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company's stock worth $339,790,000 after buying an additional 216,500 shares in the last quarter. Institutional investors own 92.59% of the company's stock.

Insider Activity at Neurocrine Biosciences

In other news, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the transaction, the insider now owns 15,449 shares of the company's stock, valued at $1,951,054.21. The trade was a 13.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Stock Up 0.0 %

Shares of NASDAQ:NBIX traded up $0.01 on Friday, hitting $126.80. The company had a trading volume of 464,123 shares, compared to its average volume of 865,323. Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98. The firm's 50-day simple moving average is $121.49 and its two-hundred day simple moving average is $130.78. The firm has a market capitalization of $12.84 billion, a price-to-earnings ratio of 33.99 and a beta of 0.34.

Wall Street Analyst Weigh In

NBIX has been the subject of several analyst reports. Barclays cut their price objective on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an "overweight" rating for the company in a report on Monday, September 9th. Royal Bank of Canada lowered their price objective on Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating on the stock in a research note on Friday, October 4th. Jefferies Financial Group lifted their price objective on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a "buy" rating in a report on Monday, August 19th. Needham & Company LLC reissued a "hold" rating on shares of Neurocrine Biosciences in a report on Monday, November 11th. Finally, Piper Sandler raised Neurocrine Biosciences from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $131.00 to $159.00 in a research note on Thursday, August 29th. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $165.18.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.